Evidence map›Paper›PMID 31467127›Full record

Trial reportHaematologica2020

Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.

Jennifer Edelmann, Karlheinz Holzmann, Eugen Tausch, Emily A Saunderson, Billy M C Jebaraj, Daniela Steinbrecher, Anna Dolnik, Tamara J Blätte, Dan A Landau, Jenny Saub and 17 more

Open access · goldAbstract readClinical Trial, Phase IIMulticenter Study
In one paragraph

Trial report in Haematologica, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
2.7field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 41 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

27 authors at 8 institutions in 4 countries.

Jennifer EdelmannDepartment of Internal Medicine III, Ulm University, Ulm, Germany jennifer.edelmann@uniklinik-ulm.de.
Karlheinz HolzmannGenomics Core Facility, Ulm University, Ulm, Germany.
Eugen TauschDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Emily A SaundersonCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Billy M C JebarajDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Daniela SteinbrecherDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Anna DolnikDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Tamara J BlätteDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Dan A LandauDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Jenny SaubDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Sven EstenfelderDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Stefan IbachWissenschaftlicher Service Pharma GmbH (WiSP), Langenfeld, Germany.
Florence CymbalistaService d'Hématologie Biologique, Hôpital Avicenne, Bobigny, France.
Veronique LeblondService d'Hématologie, Hôpital Pitié-Salpêtrière, Paris, France.
Alain DelmerService d'Hématologie Clinique, CHU de Reims, Reims, France.
Jasmin BahloDepartment of Internal Medicine I, University of Cologne, Cologne, Germany.
Sandra RobrechtDepartment of Internal Medicine I, University of Cologne, Cologne, Germany.
Kirsten FischerDepartment of Internal Medicine I, University of Cologne, Cologne, Germany.
Valentin GoedeDepartment of Internal Medicine I, University of Cologne, Cologne, Germany.
Lars BullingerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Catherine J WuDepartment of Medical Oncology, Dana Farber Cancer Institute, Boston, MA, USA.
Daniel MertensDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Gabriella FiczCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
John G GribbenCentre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.
Michael HallekDepartment of Internal Medicine I, University of Cologne, Cologne, Germany.
Hartmut DöhnerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany.
Universität Ulm · DEUniversity of Cologne · DEQueen Mary University of London · GBDana-Farber Cancer Institute · USHôpital Avicenne · FRNew York Genome Center · USSorbonne Université · FRUniversité de Reims Champagne-Ardenne · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To identify genomic alterations contributing to the pathogenesis of high-risk chronic lymphocytic leukemia (CLL) beyond the well-established role of

Indexed as

Leukemia, Lymphocytic, Chronic, B-CellCell CycleGenomicsHumansMutationProspective StudiesReceptor, Notch1NOTCH1 protein, humanReceptor, Notch1

Identifiers

PMID31467127
PMCPMC7193490
OpenAlexW2971271172

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.